Photo: Penn State/flickr
Apr 29, 2013
A group of cancer experts has issued a searing indictment of the "free market economy" principles that allow pharmaceutical companies to reap enormous profits while patients remain hostages to the industry, forced to either pay high drug prices or lose their lives.
In an editorial in Blood, the journal of the American Society of Hematology, over 100 leukemia experts from around the world argue that
Unaffordable drug prices in CML [chronic myelogenous leukemia] may be preventing many patients from accessing these life-saving drugs. [...]
Grateful patients may have become the "financial victims" of the treatment success, having to pay the high price annually to stay alive.
The prices are too high and ultimately "harmful to the sustainability of our national healthcare systems," they write.
While their focus is on CML drugs, the group writes that their findings are indicative of the "spiraling prices of cancer drugs in general." For example, 11 of the 12 cancer-treating drugs the FDA approved in 2012 were priced above $100,000 per year.
A case in point is the drug imatinib, sold by Novartis under the name Glivec, which provided about $4.7 billion in annual revenues in 2012.
The experts write that it was priced at nearly $30,000 per year in 2001 but skyrocketed to $92,000 per year in 2012, even though the original price already included research costs, "new indications were developed and FDA approved," and more people were taking it. Imatinib, they write, "may have set the pace for the rising cost of cancer drugs."
The authors conclude that the Hippocratic Oath of "do no harm" they took compels them to argue against the high prices of these drugs that do harm to and may risk the lives of cancer patients.
_________________________
Why Your Ongoing Support Is Essential
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
A group of cancer experts has issued a searing indictment of the "free market economy" principles that allow pharmaceutical companies to reap enormous profits while patients remain hostages to the industry, forced to either pay high drug prices or lose their lives.
In an editorial in Blood, the journal of the American Society of Hematology, over 100 leukemia experts from around the world argue that
Unaffordable drug prices in CML [chronic myelogenous leukemia] may be preventing many patients from accessing these life-saving drugs. [...]
Grateful patients may have become the "financial victims" of the treatment success, having to pay the high price annually to stay alive.
The prices are too high and ultimately "harmful to the sustainability of our national healthcare systems," they write.
While their focus is on CML drugs, the group writes that their findings are indicative of the "spiraling prices of cancer drugs in general." For example, 11 of the 12 cancer-treating drugs the FDA approved in 2012 were priced above $100,000 per year.
A case in point is the drug imatinib, sold by Novartis under the name Glivec, which provided about $4.7 billion in annual revenues in 2012.
The experts write that it was priced at nearly $30,000 per year in 2001 but skyrocketed to $92,000 per year in 2012, even though the original price already included research costs, "new indications were developed and FDA approved," and more people were taking it. Imatinib, they write, "may have set the pace for the rising cost of cancer drugs."
The authors conclude that the Hippocratic Oath of "do no harm" they took compels them to argue against the high prices of these drugs that do harm to and may risk the lives of cancer patients.
_________________________
A group of cancer experts has issued a searing indictment of the "free market economy" principles that allow pharmaceutical companies to reap enormous profits while patients remain hostages to the industry, forced to either pay high drug prices or lose their lives.
In an editorial in Blood, the journal of the American Society of Hematology, over 100 leukemia experts from around the world argue that
Unaffordable drug prices in CML [chronic myelogenous leukemia] may be preventing many patients from accessing these life-saving drugs. [...]
Grateful patients may have become the "financial victims" of the treatment success, having to pay the high price annually to stay alive.
The prices are too high and ultimately "harmful to the sustainability of our national healthcare systems," they write.
While their focus is on CML drugs, the group writes that their findings are indicative of the "spiraling prices of cancer drugs in general." For example, 11 of the 12 cancer-treating drugs the FDA approved in 2012 were priced above $100,000 per year.
A case in point is the drug imatinib, sold by Novartis under the name Glivec, which provided about $4.7 billion in annual revenues in 2012.
The experts write that it was priced at nearly $30,000 per year in 2001 but skyrocketed to $92,000 per year in 2012, even though the original price already included research costs, "new indications were developed and FDA approved," and more people were taking it. Imatinib, they write, "may have set the pace for the rising cost of cancer drugs."
The authors conclude that the Hippocratic Oath of "do no harm" they took compels them to argue against the high prices of these drugs that do harm to and may risk the lives of cancer patients.
_________________________
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.